期刊文献+

肿瘤微环境对胃癌免疫治疗的影响 被引量:8

Impact of microenvironment on immunotherapies in gastric cancer
下载PDF
导出
摘要 胃癌是消化系统死亡率较高的恶性肿瘤,手术切除、放疗、化疗等仍是目前主要的治疗手段,但效果并不理想。随着免疫学研究的发展,免疫治疗成为肿瘤综合治疗中研究的热点,许多新兴的手段如肿瘤疫苗、免疫卡控点治疗等展现出良好的应用前景。由于胃癌发病机制复杂,肿瘤异质性明显,还有很多问题亟待解决,肿瘤微环境是影响肿瘤的发生、发展、转移的重要因素,本文就肿瘤微环境对胃癌免疫治疗的影响方面的研究成果作一综述。 Gastric cancer is one of the malignant tumors with high mortality of digestive system. At present, the main treat- ment methods of gastric cancer are surgical resection, radiotherapy and chemotherapy, however, the outcome is not as good as expec- ted. Along with the rapid development of immunology, cancer immunotherapy has become a research hotspot. Immunotherapies such as tumor vaccine and immune checkpoints targeted therapy have exhibited a promising prospect. Because of the complex pathogenesis and heterogeneity of gastric cancer, many problems still remain to be solved. Tumor microenvironment plays an important role in tumor oc- currence, development and metastasis. This article reviews the research achievements, problems and prospects of tumor microenviron- merit and immunotherapies for gastric cancer.
出处 《临床肿瘤学杂志》 CAS 2016年第11期1038-1042,共5页 Chinese Clinical Oncology
基金 国家科技支撑计划(2015BAI12B12) 国家自然科学基金(31570877 31570908 81171653) 国家自然科学基金海外及港澳学者合作研究基金(31428005) 江苏省条件建设与民生科技专项资金(BL2014034)
关键词 胃癌 肿瘤微环境 免疫治疗 Gastric cancer Tumor microenvironment Immunotherapy
  • 相关文献

参考文献1

二级参考文献10

  • 1彭枫,魏于全.肿瘤疫苗的临床研究新进展[J].癌症,2006,25(8):1059-1062. 被引量:6
  • 2周嘉嘉,陈汝福,唐启彬,周泉波,卢红伟,王捷.载5-氟尿嘧啶两亲多糖纳米粒的制备及其对肝癌细胞HepG2的杀伤作用[J].癌症,2006,25(12):1459-1463. 被引量:10
  • 3Eggert AO, Andersen MH, Voigt H, et al. Characterization of mouse MAGE-derived H-2Kbrestricted CTL epitopes [ J]. Eur J Immunol, 2004,34 ( 11 ) :3285-3290.
  • 4Zwaveling S, Ferreira MS, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides [ J ]. J Immunol,2002,169 ( 1 ) :350-358.
  • 5Bijker MS, Van Den Eeden SJ, Franken KL, et al. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC- focused antigen presentation [ J ]. Eur J Immunol,2008,38(4):1033-1042.
  • 6Melief C J, Van Der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines [ J ]. Nat Rev Cancer,2008,8 ( 5 ) : 351 - 360.
  • 7Vantomme V, Dantinne C, Amrani N, et al. Immunologic analysis of a phase Ⅰ/Ⅱ study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors [ J ]. J Immunother,2004,27 (2) : 124-135.
  • 8Akagi T, Wang X, Uto T, et al. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly ( amino acid ) derivatives [ J ]. Biomaterials, 2007, 28 (23) : 3427-3436.
  • 9Fifis T, Mottram P, Bogdanoska V, et al. Short peptide sequences containing MHC class Ⅰ and/or class Ⅱ epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice [ J ]. Vaccine,2004,23 (2) :258-266.
  • 10Park JH, Kwon nanoparticles cholanic acid et al. Self-assembled on glycol chitosan bearing 5beta- GD peptide delivery [ J ]. J Control Release, 2004,95 ( 3 ) : 579 -588.

共引文献12

同被引文献99

引证文献8

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部